454/2009 Sb.
GOVERNMENT REGULATION
of 7 November. December 2009,
amending, for the purposes of the Criminal Code provides for what is considered to be a substance
having an anabolic and other hormonal effect and what is their greater
quantity, and what, for the purposes of the Criminal Code considers the method
in terms of increasing the oxygen transfer in the human organism and for other
method with the dopingovým effect
Modified: 2/2012 Sb.
Government orders under section 289 paragraph. 4 of law No. 40/2009 Coll., the criminal
code:
§ 1
For substances with anabolic and other hormonal effect within the meaning of § 288
the Penal Code shall be regarded as substances which are listed in annex No. 1.
to this regulation.
§ 2
Larger amounts of the substances with anabolic and other hormonal effect
within the meaning of § 288 of the criminal code means more than one blister,
injection or similar usually indivisible medicine pack containing the following
substances or similar amounts of these substances in a special dopingovém
of the product.
§ 3
A method of increasing the oxygen transport in the body
and for the other methods with dopingovým effect within the meaning of section 288 of the criminal
code, consider the methods that are listed in annex 2 to this
of the regulation.
§ 4
This Regulation shall enter into force on 1 January 2000. January 1, 2010.
Prime Minister:
Ing. Fischer, CSc in r.
Minister of Justice:
JUDr. Kabelo in r.
Annex 1
Substances with anabolic and other hormonal effect
And.
ANABOLIC AGENTS
1. Anabolic Androgenic Steroids (AAS):
and) Exogenous AAS, including: 1-androstendiol
(5a-androst-1-en-3b, 17b-diol); 1-androstenedione
(5a-androst-1-Ene-3.17-Dione); bolandiol (19-norandrostendiol);
bolasteron; boldenone; boldion (androsta-1.4-diene-3.17-Dione);
calusteron; clostebol; danazol (17a-ethynyl-17b-hydroxyandrost-
4-eno [2,3-d] isoxazol); dehydrochlormetyltestosteron (4-chloro-
17B-hydroxy-17a-metylandrosta-1.4-dien-3-one); desoxymetyltestosteron
(17a-methyl-5a-androst-2-en-17b-ol); drostanolon; etylestrenol
(19-nor-17a-pregn-4-Ene-17-ol); fluoxymesterone; formebolon; furazabol
(17b-hydroxy-17a-methyl-5a-androstano [2,3-c]-furazan); gestrinon;
4-hydroxytestosteron (4, 17b-dihydroxyandrost-4-en-3-one); mestanolon;
mesterolone; metenolon; methandrostenolone
(17b-hydroxy-17a-metylandrosta-1.4-dien-3-one); metandriol; metasteron
(2a, 17a-dimethyl-5-androstane-3-one-17b-ol); metyldienolon
(17b-hydroxy-17a-metylestra-4.9-diene-3-one); methyl-1-testosterone
(17b-hydroxy-17a-methyl-5a-androst-1-en-3-one); metylnortestosteron
(17b-hydroxy-17a-metylestr-4-en-3-one); metyltrienolon
(17b-hydroxy-17a-4, metylestra-9,11-trien-3-one); metyltestosteron;
miboleron; nandrolone; 19-norandrostendion (estr-4-Ene-3.17-Dione);
norboleton; norclostebol; norethandrolone; oxabolon; oxandrolone;
oxymesteron; oxymetolon; prostanozol ([3,2-c] pyrazol-5-
etioallocholan-17b-tetrahydropyranol); quinbolon; stanozolol;
stenbolon; 1-testosterone (17b-hydroxy-5a-androst-1-en-3-one);
tetrahydrogestrinon (18a-homo-pregna-4, 9,11-trien-17b-ol-3-one);
trenbolone and other substances with a similar chemical structure or similar
biological effects.
b) Endogenous AAS:
Androstendiol (androst-5-en-3b, 17b-diol) androstenedione
(androst-4-Ene-3.17-Dione), prasteron (dehydroepiandrosterone DHEA),
dihydrotestosterone, testosterone, and the following metabolites and isomers:
5A-androstane-3a, 17a-diol
5A-androstane-3a, 17b-diol
5A-androstane-3b, 17a-diol
5A-androstane-3b, 17b-diol
androst-4-Ene-3a, 17a-diol
androst-4-Ene-3a, 17b-diol
androst-5-en-3b, 17a-diol
androst-5-en-3a, 17a-diol
androst-5-en-3a, 17b-diol
androst-5-en-3b, 17a-diol
4-androstendiol (androst-4-Ene-3b, 17b-diol)
5-androstenedione (androst-5-Ene-3.17-Dione)
EPI-dihydrotestosterone
3A-hydroxy-5aandrostan-17-on
3B-hydroxy-5aandrostan-17-on
19-norandrosteron
19-noretiocholanolon
and other substances with a similar chemical structure or similar
biological effects.
2.
Other anabolic agents, including:
Clenbuterol, selective androgenových receptor modulators (SARM),
tibolone, zeranol, zilpaterol and other substances having a similar effect.
(B).
HORMONES AND RELATED SUBSTANCES
1. substances erythropoeisis stimulating (e.g. erythropoietin EPO, darbepoetin
Depot);
2. Growth hormone (hGH), insulin like growth factors (e.g..
IGF-1), mechanical growth factor (MGF);
3. the gonadotropins (hCG); and the luteinizing hormone (LH)
4. Insulin;
5. Kortikotropiny;
and other substances with a similar chemical structure or similar
biological effects and their releasing factors.
(C).
HORMONE ANTAGONISTS AND MODULATORS
1. Inhibitors of aromatáz, including:
Aminoglutethimid, anastrozole, exemestane, letrozole, formestan,
testolacton, but not limited to them.
2. selective estrogen receptor modulators (SERMS), including:
Raloxifene, tamoxifen, Toremifene, but not limited to them.
3. other estrogenic substances including:
Cyklofenil, fulvestrant, clomiphene
4. substances modifying myostatin functions including myostatin inhibitors.
Annex 2
Method with the dopingovým effect
And.
INCREASING THE OXYGEN TRANSFER
1. Blood doping, including the use of autologous, homologous or heterologous
blood or red blood cells, and similar products, of any
origin.
2. Artificial increasing consumption, transport or delivery of oxygen, involving
genetically modified hemoglobinové products (e.g. blood substitutes based on the
hemoglobin, haemoglobin mikroenkapsulované), perfluorochemicals and
efaproxiral (RSR13) and other products with a similar effect.
(B).
GENE DOPING
1. Transfer of nucleic acids or their sequences with potential
to enhance athletic performance.
2. the use of normal or genetically modified cells with the potential to
to enhance athletic performance.
3. the use of substances that directly or indirectly affect the function known for its
the influence on the performance by modifying gene expression, such as receptor
Delta peroxizomovými proliferátory/Peroxisome activated By
The activated Receptor d (PPARd) agonists/(e.g. GW 1516) and Agonists
axis proteinkinasové AMP-activated in conjunction with the PPAR delta
/PPARdelta-AMP-activated protein kinase (AMPK) axis agonists/
(e.g. AICAR).
